Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc > reposted link...you can see the need of solar power cannibas

<< Previous

Bullboard Posts

Next >>

Comment by Peanutbudderon Jan 11, 2018 5:38pm

41 Views

Post# 27337172

RE:RE:RE:RE:RE:reposted link...you can see the need of solar power cannibas

I'm nor the only one who thinks the same thing.. never saw the bid go lower then 0.001.. should be launch point......https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137609715

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments